The patient received the following adequate but unsuccessful treatment trials (including combinations) lasting at least 4 months each: 60 mg fluoxetine, 375 mg venlafaxine, 40 mg haloperidol, 6 mg risperidone, lithium (plasma levels 1.0 mEq/L), carbamazepine (plasma levels 9 µg/mL). She also had 8 clomipramine infusions (maximum 4 ampoules), with partial and unstable response for a couple of days. She refused ECT. During the last year, she has had rare mood-congruent auditory hallucinations.
We decided to try a more aggressive treatment with high dosages of intravenous (IV) clomipramine plus oral venlafaxine. The maximum dosage reached at day 15 was 6 ampoules IV clomipramine plus 225 mg oral venlafaxine.
On day 15, the patient responded with a dramatic remission of symptoms, almost to normothymic state. Her overall Hamilton Depression Rating Scale (HDRS) score decreased from 37 to 11, and her Hamilton Anxiety Rating Scale score decreased from 46 to 22. On the following HDRS indexes, her scores were as follows: depression symptoms decreased from 18 to 2; anxiety symptoms decreased from 8 to 6; insomnia symptoms decreased from 6 to 3; and nonspecific symptoms decreased from 5 to 0. This remission lasted for 37 days; then, obeying auditory hallucinations, the patient unsuccessfully attempted suicide by swallowing 30 tablets of diazepam 10 mg and thioridazine 30 mg. The mood change was acute, occurring within a few hours.
Clomipramine is not approved by the FDA for the treatment of depression; in continental Europe, however, it is considered the most effective agent, although there are only 5 published studies on its use to treat refractory depression (1) (2) (3) (4) (5) . Our report is the first one on the combined use of oral venlafaxine and clomipramine infusions. The only prior combined treatment reported concerns maprotiline.
The usual practice of infusions suggests starting with one-half ampoule of clomipramine and adding 1 ampoule every day to reach a maximum of 5 to 6 ampoules. Anecdotal data report higher dosages of 8 to 9 ampoules daily.
Kostas N Fountoulakis, MD, PhD Apostolos Iacovides, MD, PhD George St Kaprinis, MD, PhD Thessaloniki, Greece
Doxepin Increases Serum Cholesterol Levels
Dear Editor:
Doxepin is a well-known nonselective tricyclic antidepressant (TCA) that has been marketed in Germany for over 30 years and is still frequently applied. It causes common and group-specific side effects, including metabolic changes such as increases and decreases in blood sugar levels (1) . Other metabolic changes in patients treated with TCAs have occasionally been reported. For example, increased serum cholesterol in 24 patients treated with imipramine for panic disorder was observed (2) . Conversely, the same investigators also reported decreased high-density lipoprotein (HDL) cholesterol in patients on imipramine for panic disorder. Both depression patients and patients suffering from panic disorder showed an increase in the ratio of serum total cholesterol to HDL cholesterol under imipramine medication (3) . After an average of 7 months of nortriptyline treatment, 26 depression patients showed significantly elevated levels of triglycerides and very-low-density lipoproteins (VLDL); however, they did not show significant changes in cholesterol levels (4) . Further, it has been shown that the noradrenergic and specific serotonergic antidepressant (NaSSA) mirtazapine increases serum cholesterol to over 20% above the upper limit of normal in approximately 15% of patients (1) .
We describe a patient who showed a significant isolated elevation of serum cholesterol while on monotherapy with doxepin.
Case Report
A 32-year-old white woman suffering from severe recurrent depression without psychotic symptoms, diagnosed according to ICD-10 criteria, had been on venlafaxine for 20 weeks, with serum cholesterol levels within the normal range (is 201 to 221 mg/dL). She switched from venlafaxine to doxepin, and by week 21, her cholesterol rose to 271 mg/dL. In week 25, her cholesterol reached a maximum level around 320 mg/dL, which persisted for 20 more days. After she stopped taking doxepin and switched to reboxetine in week 27, her serum cholesterol gradually fell within 3 weeks from 312 mg/dL to 209 mg/dL. During this time, reboxetine was given as an antidepressant. Throughout the entire period, triglyceride levels were within the normal range.
Discussion
At present, there are limited and contradictory data with respect to changes in cholesterol levels in patients on antidepressant medications. Apart from limited data on TCAs, there are also reports on the effects of other antidepressants on lipid metabolism. A prospective study described a cholesterol-lowering effect of fluvoxamine (5) . In a controlled study comparing fluoxetine and trazodone, the trazodone group, but not the fluoxetine group, exhibited significantly decreased cholesterol after 6 weeks of treatment (6) . Elevated cholesterol levels during treatment with antidepressant medications appears to be noteworthy from 2 perspectives.
First, it is presumed that degeneration of minor cerebral vessels, possibly owing to impaired lipid metabolism, leads to a disruption of the frontosubcortical circuits that regulate mood, cognition, and movement (7) . If TCAs elevate cholesterol levels, they may increase the risk of vascular depression, which would also be an unwanted side effect of this medication.
Second, since the early 1990s, a correlation between serum cholesterol levels and suicidal ideation or depression has been the subject of debate. To date, the reported results are contradictory; they range from increased suicide risk in persons with low serum cholesterol levels (8, 9) to improved mood with dietary lowering of serum cholesterol (10) and include a nonnegative effect on mood symptoms (11) . It is possible that low serum levels or lowering of the serum cholesterol correlate differently to mood symptoms in emotionally healthy persons and in depression patients, that a decrease in cholesterol owing to diet or owing to treatment with cholesterol-lowering medications produces different effects, and that this affects the sexes differently. To our knowledge, this is the first report observing increased serum cholesterol levels in a patient treated with doxepin.
Besides the need to examine the correlation of mood symptoms and the serum levels of various lipid fractions, additional studies, including prospective studies, of the changes in serum cholesterol and triglyceride levels during therapy with TCAs and other antidepressants are necessary. We recommend screening patients treated with TCAs for changes of serum cholesterol levels, especially patients at risk for cardiovascular diseases. 
Re: Suicide: The Persisting Challenge
The recent editorial by Dr Isaac Sakinofsky (1) and the other articles appearing in the June 2003 issue of the Journal discuss a most important aspect of psychiatric practice. People at risk for suicide are vulnerable to various situations, some of which have been identified and accepted. For example, the replacement of coal gas, with its heavy concentration of carbon monoxide, by natural gas resulted in a marked drop in suicides. The use of electroconvulsive therapy (ECT) also contributed positively to preventing suicides. Unfortunately, all innovations-such as the replacement of imipramine by the monoamine oxidase inhibitors and later the selective serotonin reuptake inhibitors-have been followed by an upsurge of suicides. I recall that, when I cautiously introduced imipramine, I was impressed by the markedly reduced number of patients requiring ECT. We had a fairly large Department of Psychological Medicine in the Teaching Hospital in Birmingham, UK, and because of a bed shortage, we developed comprehensive outpatient services and a day hospital as early as 1950. In the first year of using imipramine, we reduced the numbers requiring ECT by 50%, and in the following year, by another 50%. Thus, within 2 years, only 25% of all patients with severe depression had to have a full course of ECT. As the years passed, the number grew smaller; with the advent of lithium, we lowered them further.
We did not send these "suicidals" to the several mental hospitals in the West Midlands of England. In fact, patients with severe depression were soon much less likely to be admitted to the mental hospitals in the region (2) . In my 25 years in the unit, not one of my patients committed suicide, and I have since maintained this "score." Management is a major factor in the treatment of patients with severe depression. If the family is involved, the risk explained, and their active cooperation secured, we should be able to get the patient over the major hurdle in a week or so. Preventing suicide is a major responsibility that psychiatrists have to face. It is about the only way to lose a patient. As already noted, it requires much attention to management; in this regard, psychiatrists have to resist the interference of the team, because a team can greatly disturb the management of actively suicidal patients. I used to say that 10 people who do not know are no better than 1 person who does not know.
I abolished the practice of issuing suicide caution cards to the nursing staff. I entered the following statement in the case notes: "In my opinion, this patient can be treated in the general ward of a general hospital." The nursing staff were most grateful, for they were no longer overwhelmed with suicide caution cards that could not guarantee more supervision. In fact, this practice led to less
